Vision correction surgery trial to study both eyes
This article was originally published in Clinica
Executive Summary
US vision correction company Refractec is to begin treating both eyes of patients on the same day with its conductive keratoplasty (CKT) technique as part of a modified clinical trial of hyperopia correction. The US FDA approved the change to the Phase III trial based on hyperopic stability data during a one to nine month follow-up, which were equal to or better than that of competitors in the field, according to the Irvine, California-based company.
You may also be interested in...
Teligent Calls In The Cavalry As Warning Letter Threatens To Overwhelm
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer Partners With Premier To Supply Critical Injectables
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Mark Cuban ‘Very Involved’, Insists Generics Company CEO
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.
Need a specific report? 1000+ reports available
Buy Reports